ArticleEuropean respiratory review : an official journal of the European Respiratory Society2020
Pulmonary capillary haemangiomatosis: a distinct entity?
Article in European respiratory review : an official journal of the European Respiratory Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Interventional Strategies for Children with Progressive Pulmonary Hypertension Despite Optimal Therapy: An Official American Thoracic Society Clinical Practice Guideline.American journal of respiratory and critical care medicine · 2025Guideline
- Prevalence of Sarcoidosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis.Frontiers in cardiovascular medicine · 2021Pooled it
- Identification of pulmonary arterial hypertension patients with venous or capillary involvement.American journal of respiratory and critical care medicine · 2026Article
- Pulmonary veno-occlusive disease: Insights from animal models.Vascular pharmacology · 2025Review
- Pulmonary Veno-Occlusive Disease: A Comprehensive Review of Diagnostic Challenges, Therapeutic Limitations, and Evolving Management.Advances in respiratory medicine · 2025Review
- Macrophage ferroptosis potentiates GCN2 deficiency induced pulmonary venous arterialization.Nature communications · 2025Article
- Review
- Pulmonary veno-occlusive disease: a clinical review.Breathe (Sheffield, England) · 2025Review
- Synchrotron-Based Phase-Contrast Micro-CT Combined With Histology to Decipher Differences Between Hereditary and Sporadic Pediatric Pulmonary Veno-Occlusive Disease.Pulmonary circulation · 2024Article
- The role of vasculature and angiogenesis in respiratory diseases.Angiogenesis · 2024Review
- Pulmonary veno-occlusive disease: illustrative cases and literature review.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Computed tomography of pulmonary veins: review of congenital and acquired pathologies.Pediatric radiology · 2022Review
- Pulmonary lesions induced by SARS-CoV-2 infection in domestic cats.Veterinary pathology · 2022Article
- MEK Inhibition in a Newborn withGenes · 2021Article
- Ventilatory efficiency in pulmonary vascular diseases.European respiratory review : an official journal of the European Respiratory Society · 2021Article
- Inflammation and intussusceptive angiogenesis in COVID-19: everything in and out of flow.The European respiratory journal · 2020Article
- Ultra-rare disease: an European perspective.European respiratory review : an official journal of the European Respiratory Society · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary capillary haemangiomatosis (PCH) is a rare and incompletely understood histopathological finding characterised by abnormal capillary proliferation within the alveolar interstitium, which has long been noted to share many overlapping features with pulmonary veno-occlusive disease (PVOD). But are PCH and PVOD distinct entities that occur in isolation, or are they closely intertwined manifestations along a spectrum of the same disease? The classic clinical features of both PCH and PVOD include signs and symptoms related to pulmonary hypertension, hypoxaemia, markedly impaired diffusion capacity of the lung and abnormal chest imaging with ground glass opacities, septal lines and lymphadenopathy. In recent years, increasing evidence suggests that the clinical presentation, histopathological features, genetic substrate and pathobiological mechanisms of PCH and PVOD are overlapping and usually indistinguishable. The discovery of biallelic mutations in the eukaryotic translation initiation factor 2 α kinase 4 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.